With Novartis losing patent protection for Vildagliptin in December,
the cost of therapy is expected to reduce by over 50%.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mega-diabetes-drug-to-be-cheaper-soon/articleshow/70374343.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment